SABR for T1-2a N1 NSCLC

NCT ID: NCT03321760

Last Updated: 2022-02-09

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-01-01
• Study Completion Date: 2027-12-31

Brief Summary

Conventionally fractionated radiation therapy given over 6-7 weeks alone, sequentially, or concurrent with chemotherapy have produced poor outcomes in Stage II NSCLC in most series. Stereotactic ablative radiotherapy (SABR) has been shown to be very effective and is now standard of care for Stage 1 disease. There has been initially reluctance to utilize SABR for central lung tumors because of published reports that showed an excess of toxicity when SABR was utilized; however, newer data with less intense treatment regimens suggest safety in treatment of central lung disease. The safety and efficacy of SABR in treating hilar nodes or N1 disease currently is not known fully and will be evaluated in this study.

Detailed Description

1. Primary Objectives Safety run-in - To determine the safety of SABR for the treatment of primary lung disease and N1 (hilar) node in stage T1-2a N1 NSCLC Phase II - To determine 2-year local control of SABR for T1-2a N1 NSCLC with sequential chemotherapy

2. Secondary Objectives Phase II - To determine overall and progression-free survival times, pattern of failures, and rates of ≥ grade 3 adverse events after SABR for T1-2a N1 NSCLC combined with sequential chemotherapy

Conditions

Lung Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Run-In Dose 1

10 Gy dose delivered to the primary tumor \& 10 Gy to the hilar (N1) node over 5 fractions

Group Type: EXPERIMENTAL

Stereotactic Ablative Radiation Therapy (SABR)

Intervention Type: RADIATION

SABR will be delivered to the primary disease and hilar (N1) node over 5 fractions.Reductions may be made to the hilar (N1) node according to a 3+3 design during the run-in period.

Run-In Dose -1

10 Gy dose delivered to the primary tumor \& 9 Gy to the hilar (N1) node over 5 fractions

Group Type: EXPERIMENTAL

Stereotactic Ablative Radiation Therapy (SABR)

Intervention Type: RADIATION

SABR will be delivered to the primary disease and hilar (N1) node over 5 fractions.Reductions may be made to the hilar (N1) node according to a 3+3 design during the run-in period.

Run-In Dose -2

10 Gy dose delivered to the primary tumor \& 8 Gy to the hilar (N1) node over 5 fractions

Group Type: EXPERIMENTAL

Stereotactic Ablative Radiation Therapy (SABR)

Intervention Type: RADIATION

SABR will be delivered to the primary disease and hilar (N1) node over 5 fractions.Reductions may be made to the hilar (N1) node according to a 3+3 design during the run-in period.

Phase 2

The maximum tolerated radiation dose to the hilar (N1) node from the run-in period will be used during Phase 2.

Group Type: EXPERIMENTAL

Stereotactic Ablative Radiation Therapy (SABR)

Intervention Type: RADIATION

SABR will be delivered to the primary disease and hilar (N1) node over 5 fractions.Reductions may be made to the hilar (N1) node according to a 3+3 design during the run-in period.

Interventions

Stereotactic Ablative Radiation Therapy (SABR)

SABR will be delivered to the primary disease and hilar (N1) node over 5 fractions.Reductions may be made to the hilar (N1) node according to a 3+3 design during the run-in period.

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 18 years old at time of consent

2. Ability to provide written informed consent and HIPAA authorization

3. Pathological diagnosis of NSCLC lung cancer

4. Staging PET/CT within 45 days of consult

5. EBUS or other histologic confirmation of N1 involvement (diagnosis of lung cancer should come from the hilar [N1] disease)

6. T1/2a <5cm lung primary

7. N1 disease <5cm

8. Patient refuses surgery or deemed inoperable

9. KPS of > 60

10. Baseline labs including CBC/differential and BMP within 45 days of consult

11. CBC/differential with adequate bone marrow function defined as follows:

1. Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3

2. Platelets ≥ 100,000 cells/mm3

3. Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.)

12. Adequate renal function defined as serum creatinine within normal institutional limits or creatinine clearance must be at least 20 ml/min

13. Adequate hepatic function defined as total bilirubin ≤ 3.0 x upper limit of normal (ULN) for the institution and ALT, AST, and alkaline phosphatase ≤ 3.0 x ULN for the institution

14. If a pleural effusion is present, the following criteria must be met at registration to exclude malignant involvement (incurable M1a disease):

1. When pleural fluid is visible on both the CT scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative;

2. Effusions that are minimal (i.e. not visible under ultrasound guidance) and that are too small to safely tap are eligible.

15. Women of childbearing potential and male participants must practice adequate contraception throughout the study

16. Patients with post-obstructive pneumonia are eligible provided they no longer require intravenous antibiotics at registration

17. Eligible for adjuvant chemotherapy as determined by the treating medical oncologist

Exclusion Criteria

1. Previous radiation therapy overlapping with current radiation target as determined by the discretion of the investigator

2. Inability to comply with treatment per investigator discretion.

3. Inability to follow standard of care follow up recommendations per investigator discretion.

4. Pregnant and breastfeeding women

5. Contra-indication to platinum-based two drug chemotherapy as determined by the treating medical oncologist

6. Patients with a history of chronic kidney disease or lactic acidosis

7. Severe, active co-morbidity, defined as follows:

i. Uncontrolled neuropathy ≥ grade 2 regardless of cause ii. Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months iii. Transmural myocardial infarction within the last 6 months iv. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration v. Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration vi. Severe hepatic disease, defined as a diagnosis of Child-Pugh Class B or C hepatic disease vii. HIV positive with CD4 count < 200 cells/microliter. Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count ≥ 200 cells/microliter within 30 days prior to registration. Note also that HIV testing is not required for eligibility for this protocol.

viii. End-stage renal disease (i.e. on dialysis or dialysis has been recommended).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Indiana University School of Medicine

OTHER

Sponsor Role: collaborator

Indiana University

OTHER

Sponsor Role: lead

Responsible Party

Tim Lautenschlaeger

Assistant Professor of Radiation Oncology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Tim Lautenschlaeger, MD

Role: PRINCIPAL_INVESTIGATOR

Indiana University

Locations

Indiana University Health Hospital

Indianapolis, Indiana, United States

Indiana University Health Methodist Hospital

Indianapolis, Indiana, United States

Indiana University Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, United States

Countries

United States

Other Identifiers

1707319235

Identifier Type: OTHER

Identifier Source: secondary_id

IUSCC-0626

Identifier Type: -

Identifier Source: org_study_id